The company has not filed an annual or quarterly report since its Q1 FY2019 10-Q, filed May 7, 2019. Its latest SEC filing is a REVOKED from Mar 10, 2023.
10-Q for Q1 FY2019, filed May 7, 2019
The sections below describe the company as of the FY2018 annual report.
Develops and sells medicines for people with rare diseases, including metreleptin and lomitapide.
10-K for FY2018, filed Mar 15, 2019We are a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. As described…View ↗
Metreleptin, a recombinant analog of human leptin, is marketed in the U.S. under the brand name MYALEPT (metreleptin) for injection…View ↗
Lomitapide, which is marketed in the U.S. under the brand name JUXTAPID (lomitapide) capsules (“JUXTAPID”), is approved in the U.S. as an…View ↗
Customers pay for metreleptin and lomitapide when products are delivered, typically within 30 to 120 days; the company also earns royalties when sublicensees sell its products and may receive sales-based milestone payments.
10-K for FY2018, filed Mar 15, 2019The Company recognizes revenue from sales of metreleptin and lomitapide at the point in time when control transfers, typically upon…View ↗
Other RevenuesView ↗
The Company has entered into agreements where the Company licenses certain rights to its products to sublicensees and earns royalties from…View ↗
$130.4M
10-K for FY2018, filed Mar 16, 2019
$130.4M ↗
In the U.S., a specialty pharmacy distributes the medicines directly to patients; outside the U.S., third-party providers deliver them to purchasers or local distributors.
10-K for FY2018, filed Mar 15, 2019In the U.S., metreleptin and lomitapide are distributed through a single specialty pharmacy network that distributes the products directly…View ↗
10-K for FY2018, filed Mar 15, 2019
For the year ended December 31, 2018, one customer accounted for 64% of our net revenues and 35% of our accounts receivable balance.View ↗
No. It lost $108.3M in FY2018.
10-K for FY2018, filed Mar 16, 2019
−$50.1MView ↗
10-K for FY2018, filed Mar 16, 2019
−$108.3MView ↗
10-K for FY2018, filed Mar 16, 2019
−$55.9MView ↗
8-K, filed Jun 12, 2020
As announced on September 25, 2019, Amryt Pharma plc (“Amryt”) acquired 100% of the outstanding equity interests of Novelion’s former…View ↗
8-K, filed Jan 21, 2020
VANCOUVER, British Columbia, January 16, 2020 – Novelion Therapeutics Inc. (“Novelion” or the “Company”) today announced that the…View ↗
8-K, filed Jan 3, 2020
On December 31, 2019, Benjamin Harshbarger resigned from his positions as the Interim Chief Executive Officer, principal executive officer…View ↗
From an eye-drug candidate to marketed medicines
The older report describes a business centered on developing an oral synthetic retinoid for inherited retinal diseases, with no products approved for commercial distribution. The latest report describes a business selling metreleptin and lomitapide for rare diseases and developing metreleptin for additional uses.
10-K for FY2015, filed Feb 25, 2016 10-K for FY2018, filed Mar 15, 2019We are a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. As described…View ↗
Metreleptin, a recombinant analog of human leptin, is marketed in the U.S. under the brand name MYALEPT (metreleptin) for injection…View ↗
Lomitapide, which is marketed in the U.S. under the brand name JUXTAPID (lomitapide) capsules (“JUXTAPID”), is approved in the U.S. as an…View ↗
Competes with Akcea Therapeutics, Regeneron Pharmaceuticals, Sanofi, Amgen, Eli Lilly &, Alnylam Pharmaceuticals, The Medicines, Gemphire Therapeutics, and REGENXBIO
10-K for FY2018, filed Mar 15, 2019In July 2018, we received regulatory approval of metreleptin as a treatment for GL and PL in the EU and we are evaluating whether to seek…View ↗
Loading...
